// App-Quantinova.ai

4339 : Phase Ib Study Of Combination Epigenetic Therapy With 5-Azacitidine and Vorinostat In Patients With Relapsed Or Refractory DLBCL

Researchers

Presenter

  • Tiffany Tang

Principal Investigators

  • Peter Martin

  • Rebecca L. Elstrom

  • Leandro Cerchietti

  • John P. Leonard

  • Jia Ruan

  • Richard R. Furman

  • Arcania Garcia

  • June Greenberg

  • Amelyn Rodriguez

  • Alison Bender

  • Jessica Lewis

  • Ari Melnick

Medical Centers

  • Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY

  • Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY

  • Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY

  • Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY

  • Division of Hematology & Medical Oncology, Weill Cornell Medical College, New York, NY

  • Weill Cornell Medical College of Cornell University, New York, NY

  • Weill Cornell Medical College, New York, NY

  • Hematology/Oncology, Weill Cornell Medical College, New York

  • Hematology/Oncology, Weill Cornell Medical College, New York

  • Department of Medicine/Hematology-Oncology and Department of Pharmacology, Weill Cornell Medical College, New York, NY

  • Division of Hematology & Medical Oncology, Weill Cornell Medical College, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hyperbilirubinemia

  • Renal insufficiency

  • Thrombocytopenia

  • Venous thrombosis

  • Hyperglycemia

  • Neutropenia

  • Anemia

  • Diffuse large B-cell lymphoma

Biomarkers

  • Alkaline phosphatase

Drug/Treatment

  • Adcetris

  • Vidaza

  • Bendamustine

  • Vorinostat

Outcome

  • N/A


Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim